The U.S. had plans to hike duties on at least $250 billion in Chinese goods to 30% from 25% on Tuesday. Despite the partial trade deal, some banks on Sunday wrote that tariff...Marketsread more
The industry has pulled in $322 billion over the past six months, the fastest pace since the second half of 2008.Marketsread more
A technical recession occurs when there are two consecutive quarters of economic contraction.Asia Economyread more
"Deepfakes" are being used to depict people in fake videos they did not actually appear in, and can potentially affect elections, diplomacy and how markets move, experts say.Technologyread more
A spokesperson for the U.S.-backed Syrian Democratic Forces (SDF) has issued a stark warning to the international community.World Newsread more
The potential deal would shift Neumann's already diminished voting power to the Japanese conglomerate, according to the Journal.Technologyread more
U.S. President Donald Trump said that both sides reached a "very substantial phase one deal" that will address intellectual property and financial services concerns and...Asia Marketsread more
On Friday, Zedd tweeted about the ban, and CNBC verified the claim with his publicist on Saturday.China Politicsread more
Hunter's vows to forgo any foreign work follow a slew of unsubstantiated attacks by President Donald Trump accusing him of corruption.Politicsread more
Apple, the company that created the modern-day smartphone, is relying on technology customers are already extremely familiar with, like cameras, and taking a backseat when it...Technologyread more
Fisher was initially defiant amid the backlash in an interview with Bloomberg, in which he said he had "given a lot of talks, a lot of times, in a lot of places and said stuff...Personal Financeread more
Potbot uses AI to "read" through peer-reviewed medical journals to find studies on cannabinoids, the active compounds in marijuana. Using the research, it pairs 37 symptoms like insomnia, asthma and cancer with branded marijuana strains to find which type of weed is best suited to treat each one.
The company has raised $5 million to date, according to Potbotics CEO David Goldstein. Part of the reason for its success is the technology doesn't actually involve marijuana directly, making it completely legal he said. The app is available in Apple's App Store and the Google Play store. In addition, the bigger pharmaceutical companies haven't entered the space, giving the marijuana industry a "start-up mentality."
"We definitely see there's interest in the industry, for sure," Goldstein said. "It's one that has real potential in the United States and internationally. A lot of investors like non-cannabis touching entities, because they feel like they are hedging their bets a little bit."
There are some challenges, including having to look at state-by-state regulations instead of being able to scale quickly like other tech companies, he pointed out. Potbotics is focusing in the New England area for now.
Goldstein, who called the legalization of medical marijuana a "lifelong passion" of his, got the idea for Potbot after a family member got sick. There are two different cultures of marijuana users – those who seek it out for medicinal purposes versus those who use it recreationally, he said.
"She refused to get this medicine because she felt it wasn't a professional experience," Goldstein said. "There are great applications like Leafly and Weedmaps. We didn't feel like there was something that helps hit that medical patient."
Goldstein previously started a crowdfunding and marketing company called Crowdpunch, so he had experience in running a company. However, he had to convince father and co-founder Baruch Goldstein to get on board. Baruch, who holds a PhD in Mathematics, completed previous work pairing artificial intelligence with medical research. One of his projects involved using AI to finding botanical strains that would help treat pre-Alzheimer's patients.
"It was a little bit of an uphill battle convincing him, but he met some of the medical marijuana patients I introduced him too," said Goldstein. "He realized if you take a real medical approach it was the same."